We use cookies to help provide you with the best possible online experience. By using this site, you agree that we may store and access cookies on your device. You can find out more about how to set your own preferences here.
Accept cookies

Construction has started on the new R&D Laboratories Building

Lugano / Barbengo, April 09 2014

Following rapid growth during the last few years, including personnel increases, Cerbios-Pharma SA (from now on “Cerbios”) shareholders approved in 2013 the construction of a new building that will accommodate both R&D (Chemical and Biological) departments in state-of-the-art laboratories and infrastructure.
The construction started this week and the new building will be ready by the middle of 2015.
Two of the four floors will be fully dedicated to R&D (580 m2, or 6’240 sq. ft. total surface). The first floor will accommodate new offices and archives, while the basement will accommodate a new warehouse.
    
The chemical and biological R&D laboratories will be equipped according to the latest standards not only with regards to new technologies and equipment, but also containment capabilities in order to accommodate the increasing demand for the development and contract manufacturing services in both areas.
The chemical R&D department will double its current laboratory surfaces for handling HPAI (High Potency Active Ingredients) up to category 4 Safebridge.
The biological R&D department will also double its current laboratory surfaces for the development of mAbs and Recombinant Proteins based on CHO mammalian cell line, as well as for the development of new pharmaceutical Probiotics.
“After a long series of investments in production units (HPAI production plant in 2008 and Biotechnology production plant in 2012-14) it was time to renew and expand the R&D areas.” says Gabriel Haering, CEO. “Our current equipment and technologies available are already state-of-the-art, but our actual and future growth was limited by physical constraints. Having space and financial resources available this was the logical step in order to sustain growth and also give more comfortable spaces for our R&D scientists”.
Following rapid growth during the last few years, including personnel increases, Cerbios-Pharma SA (from now on “Cerbios”) shareholders approved in 2013 the construction of a new building that will accommodate both R&D (Chemical and Biological) departments in state-of-the-art laboratories and infrastructure.
The construction started this week and the new building will be ready by the middle of 2015.
Two of the four floors will be fully dedicated to R&D (580 m2, or 6’240 sq. ft. total surface). The first floor will accommodate new offices and archives, while the basement will accommodate a new warehouse.
    
The chemical and biological R&D laboratories will be equipped according to the latest standards not only with regards to new technologies and equipment, but also containment capabilities in order to accommodate the increasing demand for the development and contract manufacturing services in both areas.
The chemical R&D department will double its current laboratory surfaces for handling HPAI (High Potency Active Ingredients) up to category 4 Safebridge.
The biological R&D department will also double its current laboratory surfaces for the development of mAbs and Recombinant Proteins based on CHO mammalian cell line, as well as for the development of new pharmaceutical Probiotics.
“After a long series of investments in production units (HPAI production plant in 2008 and Biotechnology production plant in 2012-14) it was time to renew and expand the R&D areas.” says Gabriel Haering, CEO. “Our current equipment and technologies available are already state-of-the-art, but our actual and future growth was limited by physical constraints. Having space and financial resources available this was the logical step in order to sustain growth and also give more comfortable spaces for our R&D scientists”.

About Cerbios-Pharma SA

Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners world-wide.

Exclusive, third-party manufacturing services are offered by the Chemical Division for HPAIs and by the Biological Division for monoclonal antibodies, recombinant proteins and pharma probiotics.

Cerbios provides full CMC support to its world-wide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.
[[ getItemTitle(currentIndex) ]]